Editorial Material
Medicine, General & Internal
Mark Roschewski, Dan L. Longo, Wyndham H. Wilson
Summary: Large B-cell lymphoma is a spectrum of aggressive B-cell cancers with broad genetic and clinical heterogeneity. First-line chemotherapy cures most patients, but salvage chemotherapy is relatively ineffective in chemotherapy-refractory disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Hematology
Wolfgang A. Bethge, Peter Martus, Michael Schmitt, Udo Holtick, Marion Subklewe, Bastian von Tresckow, Francis Ayuk, Eva Marie Wagner-Drouet, Gerald G. Wulf, Reinhard Marks, Olaf Penack, Ulf Schnetzke, Christian Koenecke, Malte von Bonin, Matthias Stelljes, Bertram Glass, Claudia D. Baldus, Vladan Vucinic, Dimitrios Mougiakakos, Max Topp, Matthias A. Fante, Roland Schroers, Lale Bayir, Peter Borchmann, Veit Buecklein, Justin Hasenkamp, Christine Hanoun, Simone Thomas, Dietrich W. Beelen, Claudia Lengerke, Nicolaus Kroeger, Peter Dreger
Summary: A study conducted in Germany suggests that important outcome determinants of CD19-directed CAR T-cell treatment of LBCL in the real-world setting include bridging success, CAR-T product selection, LDH levels, and the absence of prolonged neutropenia and/or severe neurotoxicity.
Article
Hematology
Dai Chihara, Laura Liao, Joseph Tkacz, Anjali Franco, Benjamin Lewing, Karl M. Kilgore, Loretta J. Nastoupil, Lei Chen
Summary: This study analyzed the outcomes and costs of CAR T-cell therapy in 551 older patients (aged >= 65 years) with DLBCL. The results showed that CAR T-cell therapy was less used in older patients, especially those aged >= 75 years, and this age group had a lower rate of event-free survival. This highlights the need for more accessible, effective, and tolerable therapy in older patients.
Article
Biochemistry & Molecular Biology
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Pierre Sesques, Guillaume Manson, Guillaume Cartron, David Beauvais, Louise Roulin, Francois Xavier Gros, Marie Therese Rubio, Pierre Bories, Jacques Olivier Bay, Cristina Castilla Llorente, Sylvain Choquet, Rene-Olivier Casasnovas, Mohamad Mohty, Stephanie Guidez, Magalie Joris, Michael Loschi, Sylvain Carras, Julie Abraham, Adrien Chauchet, Laurianne Drieu La Rochelle, Benedicte Deau-Fischer, Olivier Hermine, Thomas Gastinne, Jean Jacques Tudesq, Elodie Gat, Florence Broussais, Catherine Thieblemont, Roch Houot, Franck Morschhauser
Summary: This study compared the efficacy and toxicity of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The results showed that axi-cel had better overall response rate, complete response rate, progression-free survival, and overall survival compared to tisa-cel. However, axi-cel also had higher frequency of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome compared to tisa-cel.
Article
Hematology
Andrea Kuhnl, Claire Roddie, Amy A. Kirkwood, Eleni Tholouli, Tobias Menne, Amit Patel, Caroline Besley, Sridhar Chaganti, Robin Sanderson, Maeve O'Reilly, Jane Norman, Wendy Osborne, Adrian Bloor, Sanne Lugthart, Ram Malladi, Piers E. M. Patten, Lorna Neill, Nuria Martinez-Cibrian, Hannah Kennedy, Elizabeth H. Phillips, Ceri Jones, Kirsty Sharplin, Dima El-Sharkawi, Anne-Louise Latif, Amrith Mathew, Benjamin Uttenthal, Orla Stewart, Maria A. Marzolini, William Townsend, Kate Cwynarski, Kirit Ardeshna, Arzhang Ardavan, Kate Robinson, Antonio Pagliuca, Graham P. Collins, Roderick Johnson, Andrew McMillan
Summary: This study presents the results of a large national cohort of patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with CD19 CAR-T therapy in the UK. The findings demonstrate the long-term efficacy of CAR-T treatment in LBCL patients, while emphasizing the significance of early treatment failure.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Immunology
Mariana Bastos-Oreiro, Antonio Gutierrez, Juan Luis Reguera, Gloria Iacoboni, Lucia Lopez-Corral, Maria Jose Terol, Valentin Ortiz-Maldonado, Jaime Sanz, Luisa Guerra-Dominguez, Rebeca Bailen, Alberto Mussetti, Pau Abrisqueta, Rafael Hernani, Hugo Luzardo, Juan-Manuel Sancho, Javier Delgado-Serrano, Antonio Salar, Carlos Grande, Leyre Bento, Sonia Gonzalez de Villambrosia, Daniel Garcia-Belmonte, Anna Sureda, Antonio Perez-Martinez, Pere Barba, Mi Kwon, Alejandro Martin Garcia-Sancho
Summary: This study compared the efficacy of CAR-T cell therapy with the previous standard of care for refractory large B-cell lymphoma. The results showed that CAR-T therapy had superior efficacy in terms of progression-free survival and overall survival compared to the standard of care. Among the CAR-T cohort, axi-cel showed longer progression-free survival and overall survival than tisa-cel. However, axi-cel was also associated with a higher risk of severe cytokine release syndrome and neurotoxicity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Beatrice Casadei, Lisa Argnani, Serafina Guadagnuolo, Cinzia Pellegrini, Vittorio Stefoni, Alessandro Broccoli, Laura Nanni, Alice Morigi, Ginevra Lolli, Maria Guarino, Luca Spinardi, Elisabetta Pierucci, Stefano Fanti, Michele Bartoletti, Michele Dicataldo, Elena Sabattini, Francesca Bonifazi, Pier Luigi Zinzani
Summary: Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma, and CD19 CAR T-cell therapies have been approved for treating relapsed/refractory LBCL patients, showing a manageable safety profile and high objective response rate in the standard of care setting.
Article
Oncology
Timothy S. Fenske
Summary: The Oncology Grand Rounds series aims to provide clinical context for original reports published in the Journal. This article presents a case of a 73-year-old woman with mantle cell lymphoma (MCL) who achieved remission with bendamustine and rituximab. The relevant literature is reviewed, including prospective clinical trials and large retrospective real-world cohorts. The findings highlight the challenges in frontline treatment selection for MCL patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Cell Biology
Alexander D. Heini, Ulrike Bacher, Naomi Porret, Gertrud Wiedemann, Myriam Legros, Denise Stalder Zeerleder, Katja Seipel, Urban Novak, Michael Daskalakis, Thomas Pabst
Summary: This study reports two cases of mantle cell lymphoma patients who relapsed after CAR T therapy and were treated with the bispecific CD20/CD3 T cell engaging antibody glofitamab. Both patients showed increased circulating CAR T cells and objective responses after glofitamab administration. Therapy with bispecific antibodies might offer an effective and well-tolerated option for patients with mantle cell lymphoma relapsing after CAR T therapy.
Editorial Material
Multidisciplinary Sciences
Franco Montalto
Summary: Designing courses based on people's true concerns is beneficial for both students and society.
Review
Cell Biology
Diogo S. Soares, Catarina C. F. Homem, Diogo S. Castro
Summary: Proneural genes play different roles in neural development between flies and vertebrates. In flies, they have an early neural induction function, while in vertebrates, they regulate quiescence, proliferation, and neuronal differentiation in neural stem and progenitor cells. The Drosophila proneural gene asense shows a similar expression pattern to its vertebrate counterparts, suggesting similar functions. The understanding of Asense and its vertebrate homologue, Ascl1, in neural stem/progenitor cell biology and neurogenesis regulation is discussed.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Hematology
Mayur Narkhede, Gaurav Goyal, Lauren Shea, Amit Mehta, Smith Giri
Summary: Mantle cell lymphoma (MCL) is an incurable disease, and newer targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors are increasingly used in MCL treatment. This study analyzed the treatment patterns of MCL at different stages and found that bendamustine plus rituximab chemotherapy was the most commonly used frontline regimen. BTK inhibitors were the preferred agents in second or later lines of therapy.
Review
Biochemistry & Molecular Biology
Zoufang Huang, Vivek P. Chavda, Rajashri Bezbaruah, Hemant Dhamne, Dong-Hua Yang, Hong-Bing Zhao
Summary: Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma characterized by translocation of Cyclin D1. Despite progress in understanding the causes and available treatments, MCL remains incurable. CAR-T cell therapy shows potential for treating B-cell malignancies and MCL.
Review
Biochemistry & Molecular Biology
Andrea Matucci, Susanna Bormioli, Francesca Nencini, Fabio Chiccoli, Emanuele Vivarelli, Enrico Maggi, Alessandra Vultaggio
Summary: The study explores whether patients with severe asthma and rhinosinusitis can achieve effective control of asthma and sinonasal symptoms with biological therapy. The correct definition of different endotypes and varying patient responses are crucial factors to consider when managing these comorbidities.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Waleed Alduaij, Brett Collinge, Susana Ben-Neriah, Aixiang Jiang, Laura K. Hilton, Merrill Boyle, Barbara Meissner, Lauren Chong, Tomoko Miyata-Takata, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Andrew Lytle, Kerry J. Savage, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Randy D. Gascoyne, Joseph M. Connors, Ryan D. Morin, Laurie H. Sehn, Andrew J. Mungall, Christian Steidl, David W. Scott
Summary: This study found that the molecular heterogeneity of DLBCL leads to variable outcomes with immunochemotherapy. DZsig expression extends beyond HGBCL-DH-BCL2 and captures a poor-prognosis DLBCL subgroup with short DTI, including patients unidentifiable by routine FISH testing, that should be considered for treatment intensification or novel therapies in prospective trials.
